Public record
Thymalfasin: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Adverse event reports
Most reported events in FDA adverse event reports for thymalfasin
Through 2026-10-28, FDA had received 206 adverse event reports for thymalfasin, 157 of them marked serious by the reporter. The symptom terms named most often were platelet count decreased (12), anaemia (11) and diarrhoea (11).
| Measure | Value | Note |
|---|---|---|
| All reports received | 206 | |
| Reports the reporter marked serious | 157 | death, hospitalisation, disability or similar outcome |
| Platelet count decreased | 12 reports | |
| Anaemia | 11 reports | |
| Diarrhoea | 11 reports | |
| Dysbiosis | 11 reports | |
| Pneumonia | 11 reports |
How this was calculated
Counted FAERS reports listing this active substance, then the reaction terms named most often. A report can name several reactions, and a term can describe the illness being treated and not an effect of the drug. Terms about product use or complaints rather than symptoms (for example off label use) were left out of the list.
Reports where FDA recorded thymalfasin as a single-ingredient active substance (any brand), all years to 2026-10-28
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.
Clinical studies
Registered clinical studies of thymalfasin
ClinicalTrials.gov lists 67 registered studies that name thymalfasin as an intervention as of 2026-11-11. Of these, 11 are recruiting, 24 are completed and 8 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 67 |
| Recruiting now | 11 |
| Not yet recruiting | 6 |
| Completed | 24 |
| Terminated, withdrawn or suspended | 5 |
| Phase 3 (including phase 2/3) | 8 |
| Phase 2 (including phase 1/2) | 32 |
| Phase 1 | 4 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches thymalfasin, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
Published research
Published papers mentioning thymalfasin
PubMed indexes 59 papers that mention thymalfasin in the title or abstract, 32 of them published from 2016 to 2025. The count for 2025 is 2 and for 2024 is 5.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 59 | |
| Published 2016 to 2025 | 32 | |
| Published in 2025 | 2 | |
| Published in 2024 | 5 | |
| Busiest year since 2016 | 2023 | 10 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'thymalfasin' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
Articles on Thymalfasin
- Thymosin Alpha-1 Compounding Pharmacy: 503a vs 503b Explained
- Thymosin Alpha-1 Compounding Pharmacy: How to Read a Certificate of Analysis
- Thymosin Alpha-1 Compounding Pharmacy FDA and State Board Enforcement History
- Thymosin Alpha-1 Compounding Pharmacy Quality Red Flags to Avoid
- Thymosin Alpha-1: Compounding Pharmacy Research-Only vs Medical-Grade Peptides
- Thymosin Alpha-1 Post-COVID and Long-COVID Recovery Protocol